Dose-response relationship of ultrasound contrast agent in an in vivo murine melanoma model.
Many factors affect the sensitivity and reliability of tumor vasculature assessment at the small doses of contrast agent necessary for imaging mice. In this study we investigate the dose-response relationship of ultrasound contrast agent for a minimal exposure power Doppler technique (minexPD) in a murine melanoma model. K1735 murine melanomas grown in 25 C3H/HeN mice were imaged by power Doppler ultrasound using different doses of contrast agents, Optison(R) and Definity(R). Six mice were treated with an antivascular agent, combretastatin A4-phosphate (CA4P), and imaged before and after treatment. The color-weighted fractional area (CWFA) of the peak-enhanced image was measured to assess tumor perfusion on a relative scale of 0 to 100. CWFA increased logarithmically with dose (R(2)=0.97). Treatment with CA4P resulted in pronounced reduction in tumor perfusion 2 h after contrast injection, but perfusion recovered in the tumor periphery after 2 days. CWFA was significantly different between pre- and post-treatment for all doses at 2 h and 2 days (p < 0.05, respectively). There was no significant difference detectable between the two contrast agents, Optison(R) and Definity(R) (p = 0.46). In vivo tumor enhancement in mice increases as logarithmic function with dose. Although the extent of enhancement is dose dependent, the difference between pre- and post-therapy enhancement is relatively unchanged and uniform at varying doses. The two contrast agents tested in this study performed equally well. These results suggest that quantitative contrast-enhanced power Doppler imaging is an effective method for monitoring therapy response of tumors in mice.
Seiler
Gabriela S
GS
Department of Clinical Studies, Philadelphia, School of Veterinary Medicine, University of Pennsylvania, 3900 Delancey Street, Philadelphia, PA 19104, USA. gseiler@vet.upenn.edu
Ziemer
Lisa S
LS
Schultz
Susan
S
Lee
William M F
WM
Sehgal
Chandra M
CM
D000418:Albumins / Q000008:administration & dosage*; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D003287:Contrast Media / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005466:Fluorocarbons / Q000008:administration & dosage*; D007091:Image Processing, Computer-Assisted; D008546:Melanoma, Experimental / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000188:drug therapy; D051379:Mice; D009389:Neovascularization, Pathologic / Q000000981:diagnostic imaging / Q000188:drug therapy; D013267:Stilbenes / Q000494:pharmacology; D018608:Ultrasonography, Doppler
D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; D003287:Contrast Media; C099458:FS 069; D005466:Fluorocarbons; D013267:Stilbenes; C058728:fosbretabulin; C042852:perflutren